Predictors of functional benefit of hepatitis C therapy in a ‘real-life’ cohort

Figure 1 Efficacy of treatment. Sustained virological response rates 12 wk after the end of treatment (SVR 12) are shown for patients with HCV genotype 1, 2, 3 or 4 (A-D). Patients were sub-classified for therapy regime and treatment duration.

Figure 2 Change in MELD score (A) and liver stiffness (B) from baseline to 12 wk post-therapy. A: Baseline and follow-up data at 12 wk after the end of treatment was available for n = 179 patients. Each bar represents an individual patient. Patients with a relapse in follow-up are highlighted in pale grey. B: Baseline and follow-up data at 12 wk after the end of treatment was available for n = 44 patients. Each bar represents an individual patient. Patients with a relapse in follow-up are highlighted in pale grey.

Figure 3 MELD score as a predictor of functional benefit of antiviral therapy.